Popular on EntSun
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 275
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 247
- Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick - 196
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform - 179
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide - 178
- "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society - 155
- Donna Cardellino Manager/Facilitator Signs Justin Jeansonne Country Singer-Songwriter To Exclusive Management Deal For Global Music Expansion - 139
- VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 136
- Phillip E. Walker's Hollywood Actor Jobs Dec. 10-20, 2025 PRE-TOUR Launches with SweetestVacation.com at CulverCityFilmFestival.com & Closes in the IE - 130
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor - 118
Similar on EntSun
- AI-Driven Drug Development with Publication of New Bioinformatics Whitepaper for BullFrog AI: $BFRG Strengthens Its Position in AI Drug Development
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
- $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
- U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
Elabscience® Announces Antibody Technology Upgrade and Product Portfolio Enhancement
EntSun News/11076954
HOUSTON - EntSun -- Elabscience®, a leading global biotechnology company dedicated to providing high-quality reagents and services for life science research, today announced a major technological upgrade to its antibody product line. The initiative introduces recombinant rabbit monoclonal antibody technology, representing a significant step forward in antibody innovation, production efficiency, and performance consistency.
This upgrade reflects Elabscience's continued commitment to scientific excellence and innovation, in response to the growing global demand for high-performance and highly reproducible antibody reagents.
Driving Innovation with Recombinant Antibody Technology
With the rapid advancement of recombinant antibody engineering, Elabscience has fully integrated recombinant rabbit monoclonal antibody technology into its R&D and manufacturing processes. This new platform offers outstanding specificity, batch-to-batch consistency, stability, and scalability, addressing long-standing challenges associated with traditional hybridoma-derived antibodies.
"At Elabscience, we continuously strive to improve the scientific reliability of antibody-based research," said Dr. Lan, Director of Antibody Research and Development at Elabscience®. "By introducing recombinant rabbit monoclonal antibodies, we're empowering researchers with higher-quality, more consistent, and more efficient tools to accelerate discovery in fields such as immunology, oncology, and neuroscience."
More on EntSun News
Highlights of the Technology Upgrade
1. Advanced Molecular Design
● Utilizes humanized frameworks with rabbit variable region recombination, reducing heterologous immunogenicity, ideal for long-term in vivo studies.
● Combines phage display library screening with epitope prediction algorithms, enabling the generation of high-affinity antibodies (KD < 10⁻⁹ M) against complex conformational antigens such as GPCRs and ion channels.
2. Enhanced Production Process
● Employs CHO-S suspension cell culture in serum-free media, achieving batch yields over 500 mg, a 20-fold efficiency improvement compared with traditional hybridoma methods.
● Utilizes continuous flow chromatography purification, ensuring endotoxin levels below 0.1 EU/mg and meeting rigorous standards for preclinical research.
3. Stringent Quality Control
● Performs accelerated stability testing (activity retention > 90% after 14 days at 37°C).
● All batches undergo LC-MS peptide mapping and SEC-HPLC purity testing, with monomer content ≥ 98%.
Performance Comparison
Product Type: Anti-β-actin Antibody
Rabbit Polyclonal (Old): Inter-batch CV 12-15%
More on EntSun News
Recombinant Rabbit Monoclonal (New): Inter-batch CV < 3%
Product Type: Anti-PD-1 Antibody
Rabbit Polyclonal (Old): WB detection requires 1:500 dilution
Recombinant Rabbit Monoclonal (New): WB detection possible at up to 1:5000 dilution
Product Type: Anti-GFAP Antibody
Rabbit Polyclonal (Old): Supports IHC application only
Recombinant Rabbit Monoclonal (New): Compatible with IHC/ICC/IF multiple scenarios
These advancements deliver greater sensitivity, reproducibility, and versatility across research applications.
Contact
Elabscience Biotechnology Inc.
🌐 https://www.elabscience.com
📧 orders@elabscience.com
About Elabscience®
Elabscience® develops and produces high-quality reagents, including ELISA kits, antibodies, recombinant proteins, and assay kits to support global research in immunology, oncology, metabolism, and neuroscience.
This upgrade reflects Elabscience's continued commitment to scientific excellence and innovation, in response to the growing global demand for high-performance and highly reproducible antibody reagents.
Driving Innovation with Recombinant Antibody Technology
With the rapid advancement of recombinant antibody engineering, Elabscience has fully integrated recombinant rabbit monoclonal antibody technology into its R&D and manufacturing processes. This new platform offers outstanding specificity, batch-to-batch consistency, stability, and scalability, addressing long-standing challenges associated with traditional hybridoma-derived antibodies.
"At Elabscience, we continuously strive to improve the scientific reliability of antibody-based research," said Dr. Lan, Director of Antibody Research and Development at Elabscience®. "By introducing recombinant rabbit monoclonal antibodies, we're empowering researchers with higher-quality, more consistent, and more efficient tools to accelerate discovery in fields such as immunology, oncology, and neuroscience."
More on EntSun News
- Orlando Hosts Largest Fashion Collaboration as The Fashion Hub Company Opens Its Doors in Downtown Orlando
- Circus Harmony's annual show "Misterioso" celebrates 25th anniversary weekends in February
- Revenue Optics Appoints Ljupco Icevski as Executive Advisor in Strategic Move to Accelerate Commercial Development
- Waarom brand mentions in ChatGPT steeds belangrijker worden
- Destination: Scientology Shines with Team Spirit in Columbus at 2025 Dotcomm Awards
Highlights of the Technology Upgrade
1. Advanced Molecular Design
● Utilizes humanized frameworks with rabbit variable region recombination, reducing heterologous immunogenicity, ideal for long-term in vivo studies.
● Combines phage display library screening with epitope prediction algorithms, enabling the generation of high-affinity antibodies (KD < 10⁻⁹ M) against complex conformational antigens such as GPCRs and ion channels.
2. Enhanced Production Process
● Employs CHO-S suspension cell culture in serum-free media, achieving batch yields over 500 mg, a 20-fold efficiency improvement compared with traditional hybridoma methods.
● Utilizes continuous flow chromatography purification, ensuring endotoxin levels below 0.1 EU/mg and meeting rigorous standards for preclinical research.
3. Stringent Quality Control
● Performs accelerated stability testing (activity retention > 90% after 14 days at 37°C).
● All batches undergo LC-MS peptide mapping and SEC-HPLC purity testing, with monomer content ≥ 98%.
Performance Comparison
Product Type: Anti-β-actin Antibody
Rabbit Polyclonal (Old): Inter-batch CV 12-15%
More on EntSun News
- Grandview Art & Auctions Brings the Hard Rock Hotel Art Legacy to Collectors Worldwide
- Yunishigawa Onsen's Annual "Kamakura Festival" will be held January 30 – March 1, 2026
- At Your Service Plumbing Named a 2025 Nextdoor Neighborhood Fave
- Showtime Goin' Native Comedian Marc Yaffee Comes To Wasila Friday January 30
- Attention ALL MEDIA COMPANIES: You are going to LOVE the ADVERTISING REVENUES from this very special kind of VALENTINE'S DAY PROMOTION!
Recombinant Rabbit Monoclonal (New): Inter-batch CV < 3%
Product Type: Anti-PD-1 Antibody
Rabbit Polyclonal (Old): WB detection requires 1:500 dilution
Recombinant Rabbit Monoclonal (New): WB detection possible at up to 1:5000 dilution
Product Type: Anti-GFAP Antibody
Rabbit Polyclonal (Old): Supports IHC application only
Recombinant Rabbit Monoclonal (New): Compatible with IHC/ICC/IF multiple scenarios
These advancements deliver greater sensitivity, reproducibility, and versatility across research applications.
Contact
Elabscience Biotechnology Inc.
🌐 https://www.elabscience.com
📧 orders@elabscience.com
About Elabscience®
Elabscience® develops and produces high-quality reagents, including ELISA kits, antibodies, recombinant proteins, and assay kits to support global research in immunology, oncology, metabolism, and neuroscience.
Source: Elabscience
0 Comments
Latest on EntSun News
- American Laser Study Club Announces 2026 Kumar Patel Prize in Laser Surgery Recipients: Ann Bynum, DDS, and Boaz Man, DVM
- Lineus Medical Completes UK Registration for SafeBreak® Vascular
- Creators' Rights Movement Advances Copyright Rights and Generational Ownership
- Canyons & Chefs Announces Revamped Homepage
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
- Bay Street Yard to host 'Charitable Pour' bourbon pairing dinner Jan. 21
- Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
- MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
- The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
- Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
- Anne Seidman: Within the Lines
- How Democrats Made Healthcare More Expensive in 2026
- Inkdnylon Launches Bilingual Ask Inkdnylon Platform
- Proving Humanity One Click at a Time: Joseph Neibich Nybyk on Turning Captchas into Spiritual Quests
- JS Gallery Brings Global Voices to LA Art Show 2026 with "OFF SCRIPT" Exhibition
- ANTOANETTA Partners With Zestacor Digital Marketing to Expand Online Presence for Handcrafted Luxury Jewelry
- 11 Wins, Limitless Impact: 2025 Viddy Awards Honor Scientology Media Productions
- Live Comedy Returns To Rogue River On January 23
- Marc Yaffee Comes To Stubby's Cool January 17
- 13th Annual Baton Rouge Mardi Gras Festival